ALLR, NGM

Allarity Therapeutics, Inc. (ALLR)

Price (as of October 24)

0.68USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

CMRA

Comera Life Sciences Holdings, Inc.

-0.35

MTNB

Matinas BioPharma Holdings, Inc.

-0.2

NBRV

Nabriva Therapeutics plc

-0.2

VTVT

vTv Therapeutics Inc.

-0.19

BEAM

Beam Therapeutics Inc.

-0.18

MNKD

MannKind Corporation

-0.17

NAVB

Navidea Biopharmaceuticals, Inc.

-0.17

EVAX

Evaxion Biotech A/S

-0.17

MLTX

MoonLake Immunotherapeutics

-0.16

NKTX

Nkarta, Inc.

-0.16

Show more

Highest within Industry

Symbol Correlation

ALZN

Alzamend Neuro, Inc.

0.27

APVO

Aptevo Therapeutics Inc.

0.26

WVE

Wave Life Sciences Ltd.

0.25

ARCT

Arcturus Therapeutics Holdings Inc.

0.24

ABCL

AbCellera Biologics Inc.

0.24

ALRN

Aileron Therapeutics, Inc.

0.24

ARQT

Arcutis Biotherapeutics, Inc.

0.23

ARDX

Ardelyx, Inc.

0.22

ADPT

Adaptive Biotechnologies Corporation

0.21

ANVS

Annovis Bio, Inc.

0.21

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.